# IFN-β siRNA (h): sc-39603



The Power to Question

## **BACKGROUND**

The genes encoding type I interferons (IFNs), which include 14 IFN- $\alpha$  genes, 1 IFN- $\beta$  gene, 1 IFN- $\omega$  (also known as IFN- $\alpha$  II1) gene, and a number of IFN- $\omega$  pseudogenes, are clustered on human chromosome 9p21.3. Interferons- $\alpha$  and - $\beta$  are cytokines that are widely known to induce potent anti-viral activity. IFN- $\alpha$  and - $\beta$  exert a variety of other biological effects, including anti-tumor and immunomodulatory activities and are increasingly used clinically to treat a range of malignancies, myelodysplasias and autoimmune diseases. IFN- $\omega$  is antigenically different from human IFN- $\alpha$ , IFN- $\beta$  or IFN- $\gamma$ , but is a component of natural mixtures of IFN species produced by virus-induced leukocytes or Burkitt's lymphoma cells. The Type I interferon receptor (IFN- $\alpha$ R) interacts with IFN- $\alpha$ , IFN- $\beta$  and IFN- $\omega$ , and seems to be a multisubunit receptor.

# **REFERENCES**

- 1. Adolf, G.R. 1987. Antigenic structure of human interferon  $\omega$ 1 (interferon  $\alpha$  II1): comparison with other human interferons. J. Gen. Virol. 68: 1669-1676.
- 2. Lim, J.K., et al. 1994. Intrinsic ligand binding properties of the human and bovine  $\alpha$ -interferon receptors. FEBS Lett. 350: 281-286.
- 3. Hussain, M., et al. 1996. Identification of interferon- $\alpha$  7,  $\alpha$  14, and  $\alpha$  21 variants in the genome of a large human population. J. Interferon Cytokine Res. 16: 853-859.
- 4. Mire-Sluis, A.R., et al. 1996. An anti-cytokine bioactivity assay for interferons- $\alpha$ ,  $\beta$  and  $\omega$ . J. Immunol. Methods 195: 55-61.
- Cutrone, E.C., et al. 1997. Contributions of cloned type I interferon receptor subunits to differential ligand binding. FEBS Lett. 404: 197-202.
- 6. Vannucchi, S., et al. 2005. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon- $\beta$  in cervical carcinoma cells. Oncogene 24: 2536-2546.
- 7. Siren, J., et al. 2005. IFN- $\alpha$  regulates TLR-dependent gene expression of IFN- $\alpha$ , IFN- $\beta$ , IL-28 and IL-29. J. Immunol. 174: 1932-1937.
- 8. Molnarfi, N., et al. 2005. The production of IL-1 receptor antagonist in IFN-b-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of Stat1. J. Immunol. 174: 2974-2980.

## CHROMOSOMAL LOCATION

Genetic locus: IFNB1 (human) mapping to 9p21.3.

# **PRODUCT**

IFN- $\beta$  siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see IFN- $\beta$  shRNA Plasmid (h): sc-39603-SH and IFN- $\beta$  shRNA (h) Lentiviral Particles: sc-39603-V as alternate gene silencing products.

For independent verification of IFN- $\beta$  (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-39603A, sc-39603B and sc-39603C.

#### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## **APPLICATIONS**

IFN- $\beta$  siRNA (h) is recommended for the inhibition of IFN- $\beta$  expression in human cells.

#### **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## **GENE EXPRESSION MONITORING**

IFN- $\beta$  (A1): sc-53968 is recommended as a control antibody for monitoring of IFN- $\beta$  gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

## **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor IFN- $\beta$  gene expression knockdown using RT-PCR Primer: IFN- $\beta$  (h)-PR: sc-39603-PR (20 µI, 558 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.